<DOC>
	<DOC>NCT01433510</DOC>
	<brief_summary>The purpose of this study is to assess the safety profile of specific immunotherapy with Grazax for three consecutive grass pollen seasons.</brief_summary>
	<brief_title>Tolerability of Grazax in Patients With Hayfever in Real Life Settings</brief_title>
	<detailed_description>To assess the safety profile with Grazax according to the presence or not of polysensitization and/or asthma at enrollment</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<criteria>History of grass pollen allergy Positive skin pricktest and/or positive specific IgE to grass Severe, unstable or uncontrolled asthma (FEV1&lt;70% of predicted value)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Allergic</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>